{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T02:31:33Z","timestamp":1788489093884,"version":"build-2803163510"},"reference-count":27,"publisher":"Informa UK Limited","issue":"22","license":[{"start":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T00:00:00Z","timestamp":1686096000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Glaxo Smith Kline"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.2217\/fon-2023-0020","type":"journal-article","created":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T09:10:06Z","timestamp":1686129006000},"page":"1549-1562","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":12,"title":["Drivers of physician decision-making and patient perspectives across lines of therapy in multiple myeloma in the USA"],"prefix":"10.1080","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9819-8737","authenticated-orcid":false,"given":"Amanda","family":"Ribbands","sequence":"first","affiliation":[{"name":"Adelphi Real World, Bollington,Macclesfield,\rSK10 5JB,\rUK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7956-5917","authenticated-orcid":false,"given":"Natalie","family":"Boytsov","sequence":"additional","affiliation":[{"name":"GSK,Upper Providence,\rPA 19426,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0238-6723","authenticated-orcid":false,"given":"Abigail","family":"Bailey","sequence":"additional","affiliation":[{"name":"Adelphi Real World, Bollington,Macclesfield,\rSK10 5JB,\rUK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6977-0220","authenticated-orcid":false,"given":"Boris","family":"Gorsh","sequence":"additional","affiliation":[{"name":"GSK,Upper Providence,\rPA 19426,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9618-3635","authenticated-orcid":false,"given":"Emily","family":"Luke","sequence":"additional","affiliation":[{"name":"Adelphi Real World, Bollington,Macclesfield,\rSK10 5JB,\rUK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4424-1503","authenticated-orcid":false,"given":"Annabel","family":"Lambert","sequence":"additional","affiliation":[{"name":"Adelphi Real World, Bollington,Macclesfield,\rSK10 5JB,\rUK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,6,7]]},"reference":[{"key":"e_1_3_7_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.46"},{"key":"e_1_3_7_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.2128"},{"key":"e_1_3_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00135-5"},{"key":"e_1_3_7_6_1","unstructured":"American Cancer Society\n. Cancer Statistics Center: myeloma. (Eds). (2022)."},{"key":"e_1_3_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.09.621"},{"key":"e_1_3_7_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.4600"},{"key":"e_1_3_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.03.027"},{"key":"e_1_3_7_10_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13174320"},{"key":"e_1_3_7_11_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2018.1448084"},{"key":"e_1_3_7_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02096"},{"key":"e_1_3_7_13_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14174082"},{"key":"e_1_3_7_14_1","unstructured":"Pfizer\n. Pfizer\u2019s Elranatamab Granted FDA Breakthrough Therapy Designation for Relapsed or Refractory Multiple Myeloma (2022). Available from: https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizers-elranatamab-granted-fda-breakthrough-therapy"},{"key":"e_1_3_7_15_1","unstructured":"FDA\n. FDA approves teclistamab-cqyv for relapsed or refractory multiple myeloma (2022) Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-teclistamab-cqyv-relapsed-or-refractory-multiple-myeloma"},{"key":"e_1_3_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.11.014"},{"key":"e_1_3_7_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00432-4"},{"key":"e_1_3_7_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-07018-6"},{"key":"e_1_3_7_19_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007990802457040"},{"key":"e_1_3_7_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-010352"},{"key":"e_1_3_7_21_1","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S120101"},{"key":"e_1_3_7_22_1","unstructured":"Centers for Medicare and Medicaid Services\n. Oncology Care Model. Available from: https:\/\/innovation.cms.gov\/innovation-models\/oncology-care [Accessed November 2022]. (Eds). (2022)."},{"key":"e_1_3_7_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-631200"},{"key":"e_1_3_7_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14213"},{"key":"e_1_3_7_25_1","article-title":"Treatment patterns and overall survival of patients with double-class and triple-class refractory multiple myeloma: a US electronic health record database study","author":"Wang PF","unstructured":"Wang PF , YeeCW, GorshBet al. Treatment patterns and overall survival of patients with double-class and triple-class refractory multiple myeloma: a US electronic health record database study. Leuk. Lymphoma (In press).","journal-title":"Leuk. Lymphoma"},{"key":"e_1_3_7_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0435-7"},{"key":"e_1_3_7_27_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2022-0378"},{"key":"e_1_3_7_28_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2016.10.008"},{"key":"e_1_3_7_29_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.686165"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2023-0020","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:44:43Z","timestamp":1719125083000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2023-0020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,7]]},"references-count":27,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["10.2217\/fon-2023-0020"],"URL":"https:\/\/doi.org\/10.2217\/fon-2023-0020","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,7]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-01-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-18","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}